Leading the Way in Life Science Technologies

GEN Exclusives

More »

January 1, Vol. 37, No. 1

  • Feature Articles

    • GEN CEO Perspectives: Key Challenges
    • 2017 not only ushers in a new year, but a new US presidential administration as well GEN interviewed top biotech/pharma CEOs to find out what they thought might be in store for the industry and what they would like ... more »
    • GEN CEO Perspectives: Industry Growth
    • 2017 not only ushers in a new year, but a new US presidential administration as well GEN interviewed top biotech/pharma CEOs to find out what they thought might be in store for the industry and what they would like ... more »
    • GEN CEO Perspectives: Regulatory Initiatives
    • 2017 not only ushers in a new year, but a new US presidential administration as well GEN interviewed top biotech/pharma CEOs to find out what they thought might be in store for the industry and what they would like ... more »
    • GEN CEO Perspectives: Disruptive Technologies
    • 2017 not only ushers in a new year, but a new US presidential administration as well GEN interviewed top biotech/pharma CEOs to find out what they thought might be in store for the industry and what they would like ... more »
    • Genome Editing Explores New Depths
    • MaryAnn Labant
    • Classical gene therapy took several decades to advance from proof of concept to clinical applications In contrast, newer forms of gene therapy, such as those exploiting the CRISPR-Cas9 gene-editing system, may take less than a single decade to do the ... more »
    • Phenotypic Screens Take Atypical Course
    • DeeAnn Visk
    • Drug discovery isn’t content with target-based screening It isn’t even satisfied with the recent resurgence in phenotypic screening No, it is holding out for something else, something even more informative—disease-relevant phenotypic assays... more »
    • Cell-Based Assays Keep Biosimilars on Track
    • Meghaan M. Ferreira
    • The cell-based assay has become a mainstay of drug development, addressing new concerns raised by the advent of biologics These concerns include the difficulties inherent in characterizing drug efficacy and patient safety in the context of immunogenicity Whereas small molecule ... more »